<DOC>
	<DOCNO>NCT00230321</DOCNO>
	<brief_summary>The primary objective trial ass erythroid response darbepoetin alfa , determine change hemoglobin and/or red blood cell ( RBC ) transfusion-dependence describe safety profile darbepoetin alfa patient MDS . The secondary objective ass bone marrow progenitor BFU-E growth treatment darbepoetin alfa .</brief_summary>
	<brief_title>A Study Darbepoetin Alfa Patients With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosis : Bone marrow aspirate/biopsyproven MDS &gt; 2 month prior enrollment . MDS FrenchAmericanBritish ( FAB ) subtypes refractory anemia ( RA ) , RA ring sideroblast ( RARS ) , RA excess blast ( RAEB ) , nonproliferative chronic myelomonocytic leukemia ( CMML ) [ WBC &lt; 12,000/ml ] . Patients must untransfused hemoglobin &lt; 10.0 g/dL and/or patient must red cell transfusiondependent period least 2 month prior study entry . Laboratory : Bilirubin &lt; = 2 mg/dL ALT/SGPT &lt; = 2.5 x upper limit normal ( ULN ) Normal renal function ( Stanford : serum creatinine &lt; 1.2 mg/dL [ male ] , &lt; 1.0 mg/dL [ female ] ; Vanderbilt : &lt; 1.5 mg/dL ) . Age : &gt; = 18 Other : ECOG performance status 02 . Patients may receive standard supportive care , include transfusion antibiotic require . Patients must rHuEPO naive must receive prior treatment rHuEPO &gt; = 40,000 U/week 4 week . Patients secondary MDS prior allogeneic bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>